Double-stranded RNA for regulating angiotensinogen gene expression, and conjugate, pharmaceutical composition and use thereof
Regulating the expression of angiotensin genes through double-stranded RNA and siRNA conjugates, solving the problems of short efficacy and many side effects of existing hypertensive treatment drugs, achieving effective inhibition of AGT and disease treatment potential, and having high safety Sexual and persistent effects.
Patent Information
- Application Number
- PCT/CN2024/083434
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-01-15
- Filing Date
- 2024-03-25
- Publication Date
- 2024-11-21
AI Technical Summary
The existing hypertensive treatment drugs have problems such as short duration of efficacy, many side effects, and poor patient compliance, especially the high dose of nucleic acid drugs targeted at angiotensin (AGT) and insufficient effect, which cannot meet clinical needs.
Provided a double-stranded RNA, including a sense strand and an antisense strand, for regulating angiotensin gene expression, in the form of siRNA conjugates and pharmaceutical compositions, for the preparation of agents that regulate AGT expression for treatment-related disease.
It has achieved effective inhibition of the expression of angiotensin AGT, which has good tissue specificity, high safety, long duration of drug efficacy and high drug compliance, significantly improving the efficacy and safety.
Smart Images

Figure CN2024083434_21112024_PF_FP_ABST
Abstract
Description
Double-stranded RNA for regulating angiotensinogen gene expression, its conjugate, pharmaceutical composition and use Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to a double-stranded RNA for regulating angiotensinogen gene expression, a conjugate thereof, a pharmaceutical composition and uses thereof. Background Art
[0002] Hypertension is one of the most important risk factors for cardiovascular and cerebrovascular diseases. Long-term hypertension will cause damage to multiple target organs in the human body, such as coronary heart disease, heart failure, stroke, peripheral vascular disease and kidney damage. Its harm is even worse than hypertension itself. Therefore, effective blood pressure control is the key to preventing and treating hypertension and target organ damage.
[0003] Currently, there are four main types of medications for the treatment of hypertension: 1) Diuretics: Thiazides are the most commonly used, with hydrochlorothiazide being a common one. Their primary adverse effects are hypokalemia and effects on lipid, blood sugar, and uric acid metabolism. Other side effects include fatigue and increased urine output. They are contraindicated in patients with gout. 2) Beta-blockers: These are suitable for patients with varying degrees of hypertension, particularly young and middle-aged patients with a rapid heart rate or those with angina or chronic heart failure. Their efficacy is relatively poor in the elderly. 3) Calcium channel blockers: They have a good antihypertensive effect in the elderly and also have a significant antihypertensive effect in alcoholics. They can also be used in patients with comorbid diabetes, coronary artery disease, or peripheral vascular disease. Long-term treatment also has anti-atherosclerotic effects. 4) Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: These are particularly suitable for hypertensive patients with heart failure, myocardial infarction, atrial fibrillation, proteinuria, impaired glucose tolerance, or diabetic nephropathy.
[0004] Treatment of hypertension requires long-term maintenance treatment, and treatment cannot be stopped at will or the treatment plan cannot be changed frequently. After stopping antihypertensive drugs, most patients return to their original blood pressure levels within half a year. Due to the long-term nature of antihypertensive treatment, patient compliance with treatment is very important. At present, the drugs on the market for hypertension-related diseases are mainly small molecule drugs, which need to be taken daily, have a short duration of efficacy, and poor patient compliance; and most drugs are accompanied by varying degrees of side effects; some patients still cannot control their blood pressure well after taking a combination of drugs. Obviously, these drugs cannot meet existing clinical needs, so new drugs for the treatment of such diseases are becoming more and more urgent.
[0005] The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that plays a role in blood pressure regulation, and its inhibition has a well-established antihypertensive effect. Angiotensinogen (AGT), the most upstream precursor protein in the RAAS pathway, is specifically expressed in the liver. Numerous studies have made significant progress in understanding the molecular mechanisms and clinical relevance of AGT to hypertension and atherosclerosis, making it a target for the treatment of cardiovascular disease.
[0006] Currently, two nucleic acid drugs targeting AGT are in Phase II clinical trials: Alnylam's siRNA and Ionis' antisense oligonucleotide (ASO). Both of these nucleic acid drugs currently undergoing clinical trials use high doses, leaving room for improvement in efficacy. Clearly, these drugs cannot meet existing clinical needs, leading to an increasing urgency for new treatments for these diseases.
[0007] Summary of the Invention
[0008] The object of the present invention is to provide a double-stranded RNA for regulating angiotensinogen gene expression, its conjugate, pharmaceutical composition and use, which can effectively inhibit the expression of AGT protein.
[0009] In order to achieve the above object, the technical solution adopted by the present invention is:
[0010] In a first aspect, the present invention provides a double-stranded RNA comprising a sense strand and an antisense strand, wherein each nucleotide in the double-stranded RNA is independently a modified or unmodified nucleotide, the sense strand comprises a nucleotide sequence selected from one of the nucleotide sequences shown in SEQ ID NOs. 1 to 109 or a nucleotide sequence in which no more than three base mutations are present in the above sequences, and the antisense strand comprises a nucleotide sequence selected from one of the nucleotide sequences shown in SEQ ID NOs. 110 to 218 or a nucleotide sequence in which no more than five base mutations are present in the above sequences.
[0011] According to certain embodiments, the positive strand includes a nucleotide sequence with no more than two base mutations and no more than one base mutation compared to any one of the nucleotide sequences shown in SEQ ID NOs. 1 to 109.
[0012] According to certain embodiments, the base mutation of the positive chain can be at any position of the nucleotide sequence, for example, any one, two or three of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth and nineteenth positions.
[0013] According to certain embodiments, the antisense strand comprises a nucleotide sequence with no more than 5 base mutations, a nucleotide sequence with no more than 4 base mutations, a nucleotide sequence with no more than 3 base mutations, a nucleotide sequence with no more than 2 base mutations, or a nucleotide sequence with no more than 1 base mutation compared to any one of the nucleotide sequences shown in SEQ ID NOs. 110 to 218.
[0014] According to certain embodiments, the base mutation of the antisense strand can be at any position of the nucleotide sequence, for example, any one, two, three, four or five of the first, second, third, fourth, fifth, sixth, seventh, eighth, ninth, tenth, eleventh, twelfth, thirteenth, fourteenth, fifteenth, sixteenth, seventeenth, eighteenth, nineteenth, twentieth and twenty-first positions.
[0015] According to certain embodiments, in the 5' to 3' direction, the base mutation of the sense strand is at the 3' end of its nucleotide sequence, and the base mutation of the antisense strand is at any one or more of the 5' end, positions 2 to 8, and the last two positions of the 3' end of its nucleotide sequence.
[0016] According to certain embodiments, the base mutation includes base substitution, insertion or deletion.
[0017] In certain embodiments, the modified nucleotides are a combination of one or more of 2'-methoxy-modified nucleotides, 2'-fluoro-modified nucleotides, 2'-O-CH2-CH2-O-CH3-modified nucleotides, 2'-O-CH2-CH=CH2-modified nucleotides, 2'-CH2-CH2-CH=CH2-modified nucleotides, 2'-deoxy-nucleotides, 2'-methoxyethyl-modified nucleotides, phosphorothioate-modified nucleotides, VP-modified nucleotides, LNA, ENA, cET BNA, UNA, GNA, and SAFE-01, wherein R1 in the structural formula shown in SAFE-01 is H, OH, or CH3, and Base is a natural nucleobase, a modified nucleobase, a universal base, or an H atom.
[0018] Furthermore, R1 is CH3.
[0019] In certain embodiments, the number of modified nucleotides in the sense strand is one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, or nineteen.
[0020] In certain embodiments, the number of modified nucleotides in the antisense strand is one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty, or twenty-one.
[0021] In certain embodiments, all of the nucleotides in the sense strand and the antisense strand are modified nucleotides.
[0022] In certain embodiments, in the 5' to 3' direction, the nucleotides at positions 7, 8, and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides; in the 5' to 3' direction, the nucleotides at positions 2, 6, 14, and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides; at least one of the following linkages between nucleotides in the double-stranded RNA is a phosphorothioate linkage:
[0023] the connection between the first nucleotide and the second nucleotide at the 5' end of the sense strand;
[0024] the connection between the second nucleotide and the third nucleotide at the 5' end of the sense strand;
[0025] the connection between the first nucleotide and the second nucleotide at the 3' end of the sense strand;
[0026] the connection between the second nucleotide and the third nucleotide at the 3' end of the sense strand;
[0027] the connection between the first nucleotide and the second nucleotide at the 5' end of the antisense strand;
[0028] the connection between the second nucleotide and the third nucleotide at the 5' end of the antisense strand;
[0029] the connection between the first nucleotide and the second nucleotide at the 3' end of the antisense strand;
[0030] The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
[0031] In other embodiments, in the 5' to 3' direction, the 7th, 9th and 11th nucleotides of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides; in the 5' to 3' direction, the 2nd, 14th and 16th nucleotides of the antisense strand are 2'-fluoro-modified nucleotides; and at least one of the following linkages between nucleotides in the double-stranded RNA is a phosphorothioate linkage:
[0032] the connection between the first nucleotide and the second nucleotide at the 5' end of the sense strand;
[0033] the connection between the second nucleotide and the third nucleotide at the 5' end of the sense strand;
[0034] the connection between the first nucleotide and the second nucleotide at the 5' end of the antisense strand;
[0035] the connection between the second nucleotide and the third nucleotide at the 5' end of the antisense strand;
[0036] the connection between the first nucleotide and the second nucleotide at the 3' end of the antisense strand;
[0037] The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
[0038] Further, in these embodiments, the nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides; or,
[0039] From the 5' to 3' direction, the 12th nucleotide of the antisense strand is a 2'-fluoro-modified nucleotide, and the nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides; or
[0040] According to the 5' to 3' direction, the 7th nucleotide of the antisense strand includes the structural formula The modification shown, wherein R1 is H, OH or CH3, Base is a natural nucleobase, a modified nucleobase, a universal base or an H atom; the nucleotide at position 12 of the antisense strand is a 2'-fluoro-modified nucleotide, and the nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides; or,
[0041] According to the 5' to 3' direction, the 7th nucleotide of the antisense strand includes the structural formula The modification shown, wherein R1 is H, OH or CH3, Base is a natural nucleobase, a modified nucleobase, a universal base or an H atom; the nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides.
[0042] In some embodiments, in the 5' to 3' direction, the nucleotides at positions 7, 8, and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides;
[0043] From the 5' to 3' direction, the nucleotides at positions 2, 14, and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions are 2'-methoxy-modified nucleotides; or, the nucleotides at positions 2, 12, 14, and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions are 2'-methoxy-modified nucleotides;
[0044] At least one of the following linkages between nucleotides in the double-stranded RNA is a phosphorothioate linkage:
[0045] the connection between the first nucleotide and the second nucleotide at the 5' end of the sense strand;
[0046] the connection between the second nucleotide and the third nucleotide at the 5' end of the sense strand;
[0047] the connection between the first nucleotide and the second nucleotide at the 5' end of the antisense strand;
[0048] the connection between the second nucleotide and the third nucleotide at the 5' end of the antisense strand;
[0049] the connection between the first nucleotide and the second nucleotide at the 3' end of the antisense strand;
[0050] The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
[0051] In certain embodiments, the double-stranded RNA is selected from Table 1, Table 2 or Table 7.
[0052] In other specific embodiments, the sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or,
[0053] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUmUmCmAmUmCfCmAfGmUfUmGmAmsGmsGm-3'; or,
[0054] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUgoUmCmAmUmCfCmAfGmUfUmGmAmsGmsGm-3'; or,
[0055] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmTgoUmCmAmUmCfCmAfGmUfUmGmAmsGmsGm-3'; or,
[0056] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUgoUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or,
[0057] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmTgoUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or,
[0058] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmAmCmAm-3', and the antisense strand is 5'-VP-UmsGfsUmUmUmCfUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or,
[0059] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmAmCmAm-3', and the antisense strand is 5'-VP-UmsGfsUmUmUmCfUgoUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or,
[0060] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCfUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or,
[0061] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or,
[0062] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUmUmCmAmUmCfCmAfGmUfUmGmAmsGmsGm-3'; or,
[0063] The sense strand of the double-stranded RNA is 5'-AmsAmsAmAmCmUmCfCfCfUmCmAmAmCmUmGmGmAmUm-3', and the antisense strand is 5'-AmsUfsCmCmAmGfUmUmGmAmGmGmAfGmUfUmUmUmUmsGmsCm-3'; or,
[0064] The sense strand of the double-stranded RNA is 5'-CmsAmsAmGmGmUmGfGfAfGmGmGmUmCmUmCmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmGmAmGfAmCmCmCmUmCmCmAfCmCfUmUmGmsUmsCm-3'; or,
[0065] The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCfUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or,
[0066] The sense strand of the double-stranded RNA is 5'-CmsAmsGmCmAmAmAfAfCfUmCmCmCmUmCmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmGmAfGmGmGmAmGmUmUmUfUmGfCmUmGmsGmsAm-3'; or,
[0067] The sense strand of the double-stranded RNA is 5'-CmsCmsAmCmAmAmUfGfAfGmAmGmUmAmCmCmUmGmUm-3', and the antisense strand is 5'-AmsCfsAmGmGmUfAmCmUmCmUmCmAmUfUmGfUmGmGmsAmsUm-3'; or,
[0068] The sense strand of the double-stranded RNA is 5'-UmsUmsCmUmUmGmGfGfCfUmUmCmCmGmUmAmUmAmUm-3', and the antisense strand is 5'-AmsUfsAmUmAmCfGmGmAmAmGmCmCmCfAmAfGmAmAmsGmsUm-3'; or,
[0069] The sense strand of the double-stranded RNA is 5'-AmsUmsUmCmCmUmGfUfUfUmGmCmUmGmUmGmUmAmUm-3', and the antisense strand is 5'-AmsUfsAmCmAmCfAmGmCmAmAmAmCmAfGmGfAmAmUmsGmsGm-3';
[0070] Among them, the structural formula of Ugo is The structural formula of Tgo is
[0071] The second aspect of the present invention provides an siRNA conjugate, which includes the above double-stranded RNA and a conjugated group conjugated to any position of the double-stranded RNA.
[0072] Furthermore, one, two, three or four consecutively connected conjugated groups are connected to any position of the double-stranded RNA.
[0073] In certain embodiments, the conjugate group is attached to the 3' end and / or the 5' end of the sense strand.
[0074] In certain embodiments, the siRNA conjugate has any one of the following structures:
[0075] in, represents double-stranded RNA;
[0076] R represents any one of the conjugated groups having the following structures:
[0077] Wherein, Y is O or S
[0078] The third aspect of the present invention provides a pharmaceutical composition comprising the above-mentioned siRNA or the above-mentioned siRNA conjugate, and a pharmaceutically acceptable carrier or excipient.
[0079] In certain embodiments, the pharmaceutical composition is used to modulate the expression of angiotensinogen AGT.
[0080] The fourth aspect of the present invention provides use of the double-stranded RNA, or the siRNA conjugate, or the pharmaceutical composition for preparing a medicament for regulating the expression of angiotensinogen AGT.
[0081] In certain embodiments, diseases associated with angiotensinogen AGT expression include critical hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, hypertension associated with low plasma renin activity or plasma renin concentration, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, unstable hypertension, hypertensive Heart disease, hypertensive nephropathy, atherosclerosis, arteriosclerosis, vascular disease, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, nocturnal hypertension, glomerulosclerosis, coarctation of the aorta, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, stroke, kidney disease, renal failure, systemic sclerosis, intrauterine growth retardation, fetal growth restriction, obesity, hepatic steatosis / fatty liver disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, glucose intolerance, type 2 diabetes mellitus, and metabolic syndrome.
[0082] The present invention also provides a method for regulating the expression of angiotensinogen AGT, comprising contacting a therapeutically effective amount of the double-stranded RNA of the present invention, or the siRNA conjugate of the present invention, or the pharmaceutical composition of the present invention with cells expressing angiotensinogen AGT or administering it to a subject in need thereof.
[0083] The present invention also provides a method for treating and / or preventing diseases associated with angiotensinogen AGT expression, comprising administering a therapeutically effective amount of the double-stranded RNA of the present invention, or the siRNA conjugate of the present invention, or the pharmaceutical composition of the present invention to a subject in need thereof.
[0084] In certain embodiments, the double-stranded RNA, or the siRNA conjugate, or the pharmaceutical composition is administered by subcutaneous injection, intravenous injection, intrathecal injection, or intramuscular injection.
[0085] Due to the application of the above technical solution, the present invention has the following advantages compared with the prior art:
[0086] The present invention has excellent activity in inhibiting angiotensinogen (AGT) expression and has great potential for treating diseases associated with angiotensinogen (AGT) expression. It also has good tissue specificity and high safety, as well as a long-lasting effect and high medication compliance. Compared with existing drugs of the same type, both efficacy and safety are significantly improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0087] FIG1 is a graph showing the residual expression level of SEAP in mouse serum after using the test conjugate of the present invention in Example 7;
[0088] FIG2 is a graph showing the relative residual expression levels of the siRNA of Example 11 in mice 7 days after administration;
[0089] FIG3 is a graph showing the relative residual expression levels of AGT protein in cynomolgus monkeys at different days after administration of the siRNA of Example 12;
[0090] FIG4 is a graph showing the systolic blood pressure test results of the siRNA of Example 13 in hypertensive cynomolgus monkeys;
[0091] FIG5 is a graph showing the diastolic blood pressure test results of the siRNA of Example 13 in hypertensive cynomolgus monkeys. DETAILED DESCRIPTION
[0092] It should be noted that, unless otherwise defined, the technical or scientific terms used in this application should have the common meanings understood by those skilled in the art.
[0093] The experimental methods in the following examples are conventional methods unless otherwise specified. The raw materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified.
[0094] definition
[0095] In the above and below, 2'-methoxy-modified nucleotides refer to nucleotides in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is replaced by a methoxy group; similarly, 2'-fluoro-modified nucleotides, 2'-O-CH2-CH2-O-CH3-modified nucleotides, 2'-O-CH2-CH=CH2-modified nucleotides, 2'-CH2-CH2-CH=CH2-modified nucleotides, 2'-deoxynucleotides, and 2'-methoxyethyl-modified nucleotides refer to nucleotides in which the hydroxyl group at the 2' position of the ribose group of the nucleotide is replaced by the corresponding group.
[0096] Phosphorothioate-modified nucleotides refer to nucleotides in which one of the oxygen atoms in the phosphodiester bond of the phosphate group is replaced by a sulfur atom.
[0097] VP-modified nucleotides refer to nucleotides in which the phosphate group of the nucleotide is replaced by a vinyl phosphate group. In some embodiments, the 5'-terminal phosphate group of the antisense strand is replaced by VP.
[0098] LNA is shown in formula (1), ENA is shown in formula (2), cET BNA is shown in formula (3), UNA is shown in formula (4), GNA is shown in formula (5), and VP is shown in formula (6):
[0099] In the above formulae (1) to (6), Base represents a natural nucleobase, a modified nucleobase, or a universal base, such as A, U, G, or C. In the above formulae (4) to (6), R is selected from H, OH, or alkoxy (O-alkyl).
[0100] The structural formula of SAFE-01 is wherein R1 is H, OH or CH3, and Base is a natural nucleobase, a modified nucleobase, a universal base or an H atom. According to some embodiments, R1 is H. According to some embodiments, R1 is OH. According to some embodiments, R1 is CH3.
[0101] The capital letters A, C, G, and U represent adenosine-3'-phosphate, cytidine-3'-phosphate, guanosine-3'-phosphate, and uridine-3'-phosphate, respectively; the lowercase letter m indicates that the nucleotide adjacent to the left of the letter m is a 2'-methoxy-modified nucleotide; the lowercase letter f indicates that the nucleotide adjacent to the left is a 2'-fluoro-modified nucleotide; the lowercase letter s in the middle of the capital letter indicates that the two nucleotides adjacent to the left and right of s are connected by thiophosphate groups; when s is the first at the 3' end, it means that the terminal of the nucleotide adjacent to the left of the letter s is a thiophosphate group.
[0102] In the foregoing and following text, particularly when describing the methods for preparing the siRNA, pharmaceutical compositions, or siRNA conjugates disclosed herein, unless otherwise specified, the nucleoside monomers referred to herein are modified or unmodified nucleoside phosphoramidite monomers used in solid-phase phosphoramidite synthesis, depending on the type and sequence of nucleotides in the siRNA or siRNA conjugate to be prepared. Solid-phase phosphoramidite synthesis is a method used in RNA synthesis that is well known to those skilled in the art. The nucleoside monomers used in the present disclosure are all commercially available.
[0103] In the context of the present disclosure, unless otherwise specified, "conjugation" refers to the covalent bonding of two or more chemical moieties, each with a specific function, to one another; accordingly, "conjugate" refers to a compound formed by covalent bonding of the chemical moieties. Furthermore, "siRNA conjugate" refers to a compound formed by covalent bonding of one or more chemical moieties with a specific function to siRNA. siRNA conjugate should be understood as a general term for multiple siRNA conjugates or an siRNA conjugate represented by a certain chemical formula, depending on the context. In the context of the present disclosure, "conjugated molecule" should be understood as a specific compound that can be conjugated to siRNA through a reaction to ultimately form the siRNA conjugate of the present disclosure.
[0104] Various hydroxy protecting groups can be used in the present disclosure. In general, protecting groups make chemical functional groups insensitive to specific reaction conditions, and can be added and removed on the functional group in the molecule without substantially damaging the rest of the molecule. Representative hydroxy protecting groups are disclosed in Beaucage et al., Tetrahedron 1992, 48, 2223-2311, and Greene and Wuts, Protective Groups in Organic Synthesis, Chapter 2, 2d ed, John Wiley & Sons, New York, 1991, each of which is incorporated herein by reference. In some embodiments, the protecting group is stable under alkaline conditions, but can be removed under acidic conditions. In some embodiments, non-exclusive examples of hydroxy protecting groups that can be used herein include dimethoxytrityl (DMT), monomethoxytrityl, 9-phenylxanthine-9-yl (Pixyl) and 9-(p-methoxyphenyl)xanthine-9-yl (Mox). In some embodiments, non-exclusive examples of hydroxy protecting groups that may be used herein include Tr (trityl), MMTr (4-methoxytrityl), DMTr (4,4'-dimethoxytrityl), and TMTr (4,4',4"-trimethoxytrityl).
[0105] The pharmaceutically acceptable carriers described in the present disclosure may be carriers conventionally used in the field of siRNA administration, such as, but not limited to, magnetic nanoparticles (e.g., nanoparticles based on Fe3O4 or Fe2O3), carbon nanotubes, mesoporous silicon, calcium phosphate nanoparticles, polyethylenimine (PEI), polyamidoamine (PAMAM) dendrimer, poly(L-lysine, PLL), chitosan, 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), poly (D&L-lactic / glycolic acid) copolymer (PLGA), poly(2-aminoethyl ethylene phosphate), ... The pharmaceutically acceptable excipients may include one or more of poly(2-dimethylaminoethyl methacrylate), poly(2- ...
[0106] As used herein, "optional" or "optionally" means that the subsequently described event or circumstance can or cannot occur, and that the description includes instances where the event or circumstance occurs and instances where it does not.
[0107] The term "subject," as used herein, refers to any animal, such as a mammal or marsupial. Subjects of the present disclosure include, but are not limited to, humans, non-human primates (e.g., rhesus monkeys or other types of macaques), mice, pigs, horses, donkeys, cattle, rabbits, sheep, rats, and any type of poultry.
[0108] As used herein, "treatment" refers to an approach for obtaining beneficial or desired results, including but not limited to a therapeutic benefit. "Therapeutic benefit" means eradication or amelioration of the underlying disorder being treated. Furthermore, a therapeutic benefit is achieved by eradication or amelioration of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the subject, even though the subject may still be afflicted with the underlying disorder.
[0109] As used herein, "prevention" refers to an approach to obtaining beneficial or desired results, including but not limited to prophylactic benefit. To obtain a "prophylactic benefit," siRNA, siRNA conjugate, or pharmaceutical composition can be administered to a subject at risk for a particular disease, or to a subject reporting one or more physiological symptoms of a disease, even though a diagnosis of the disease may not have yet been made.
[0110] The technical solution provided by the present invention is further described below in conjunction with specific examples. The following examples are only used to illustrate the present invention and do not limit the scope of protection of the present invention. SD hereafter represents standard deviation.
[0111] Example 1 Synthesis of siRNA
[0112] In this article, if the actual source of the reagents is not given, such reagents can be obtained from any supplier of molecular biology reagents and have the quality / purity standards that meet the molecular biology application standards.
[0113] siRNA sequences were synthesized at a 200 nmol scale using solid-support-mediated phosphoramidite chemistry on a Dr. Oligo 48 synthesizer (Biolytic). The solid support was a general-purpose solid support (Shenzhen Comma Biotech). Nucleoside monomer starting materials, including 2'-F RNA and 2'-O-methyl RNA, were purchased from Shanghai Zhaowei or Suzhou Jima. The coupling time for all phosphoramidites (50 mM in acetonitrile) was 6 minutes. 5-Ethylthio-1H-tetrazole (ETT) was used as the activator (0.6 M in acetonitrile). A 0.22 M solution of PADS in a 1:1 volume ratio of acetonitrile and collidine (Suzhou Kelema) was used as the sulfurization reagent. The sulfurization reaction time was 3 minutes. An iodine pyridine / water solution (Kelema) was used as the oxidant. The oxidation reaction time was 2 minutes.
[0114] After solid-phase synthesis, the oligonucleotides were cleaved from the solid support and soaked in a 3:1 28% ammonia and ethanol solution at 50°C for 16 hours. The mixture was then centrifuged at high speed, and the supernatant was transferred to another centrifuge tube. After evaporation, the supernatant was purified using C18 reverse-phase chromatography with a mobile phase of 0.1 M TEAA and acetonitrile, and DMTr was removed using a 3% trifluoroacetic acid solution. The target oligonucleotide was collected and lyophilized, identified as the target product by LC-MS, and quantified by UV (260 nm).
[0115] The resulting single-stranded oligonucleotides are annealed in equal molar ratios, along the two complementary sequences. The resulting double-stranded siRNA is dissolved in 1X PBS and adjusted to the desired concentration. These monomers are linked to form the oligonucleotide via 5'-3'-phosphodiester bonds.
[0116] Table 1 below shows the unmodified sense and antisense strand sequences of AGT siRNA, and Table 2 below shows the modified sense and antisense strand sequences of AGT siRNA.
[0117] Table 1
[0118] Table 2
[0119] Example 2 Preparation of conjugated groups
[0120] 1. Preparation of compound SA51 (I-1-7)
[0121] 1.1. Preparation of Intermediate 2-1
[0122] Compound (R)-(+)-N-benzyl-3-hydroxypyrrolidine (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) (16.9 mmol, 3.0 g) and imidazole (3.0 equiv, 50.7 mmol, 3.45 g) were placed in a clean, dry reaction flask, 50 mL of acetonitrile was added, and tert-butyldimethylsilyl chloride (1.3 equiv, 21.9 mmol, 3.31 g) was slowly added at room temperature, and then stirred at room temperature for 12 hours. After the reaction, 100 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with 100 mL of saturated sodium bicarbonate solution and 100 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1-5 / 1) to obtain a colorless oil compound 2-1 (4.9 g, 16.8 mmol, 99% yield). Compound 2-1 Molecular formula: C 17 H 29 ONSi, molecular weight: 291.2, LC-MS measured: 292.4 (M+H).
[0123] 2.2 Preparation of intermediate 2-2
[0124] Compound 2-1 (16.8 mmol, 4.9 g) was placed in a clean, dry reaction flask, 100 mL of methanol was added, and palladium carbon (wet basis, 10% Pd / C) (10% wt, 490.0 mg) was added under hydrogen at room temperature, followed by continued stirring at room temperature for 12 hours. After the reaction, the palladium carbon was removed by filtration, and the filtrate was concentrated to obtain a crude product, white solid compound 2-2 (3.31 g, 16.5 mmol, 98% yield), which was directly used in the next reaction without purification. Compound 2-2 molecular formula: C 10 H 23 ONSi, molecular weight: 201.1, LC-MS measured: 202.3 (M+H).
[0125] 2.3 Preparation of intermediate 2-3
[0126] The compound N-benzyloxycarbonyl-L-serine (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) (15.0 mmol, 3.58 g) was placed in a clean dry reaction bottle, 100 mL of dichloromethane was added, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 equiv, 22.5 mmol, 8.53 g), compound 2-2 (1.1 equiv, 16.5 mmol, 3.31 g) and N,N-diisopropylethylamine (3.0 equiv, 45.0 mmol, 5.78 g) were added at room temperature, followed by stirring at room temperature for 1 hour. After the reaction, 150 mL of dichloromethane was added to the reaction solution, and the mixture was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 10 / 1-1 / 3) to obtain a white solid compound 2-3 (4.5 g, 10.65 mmol, 63% two-step yield). Compound 2-3 molecular formula: C 21 H 34 O5N2Si, molecular weight: 422.2, LC-MS measured: 423.3 (M+H). 1 H NMR (400MHz, CDCl3): δ7.35–7.29(m,5H),5.96(dd,J=14.3,8.3Hz,1H),5.10(s,2H),4.61–4.40(m,2H),3.85–3.68(m,2H),3.65–3.4 9(m,2H),3.41(d,J=12.7Hz,1H),3.31(s,1H),1.95(qdd,J=15.0,11.8,5.3Hz,2H),1.77(s,1H),0.86(s,9H),0.06(d,J=3.1Hz,6H).
[0127] 2.4 Preparation of Intermediate 2-4
[0128] Compound 2-3 (10.65 mmol, 4.5 g) was placed in a clean, dry reaction flask, 100 mL of pyridine was added, and 4,4'-bismethoxytrityl chloride (1.2 equiv, 12.78 mmol, 4.32 g) was added at room temperature, followed by stirring at room temperature for 12 hours. After the reaction, 150 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate = 20 / 1-1 / 1) to obtain compound 2-4 (7.56 g, 10.43 mmol, 98% yield) as a light yellow oil. Compound 2-4 molecular formula: C 42 H52 O7N2Si, molecular weight: 724.3, LC-MS measured: 747.4 (M+Na). 1 H NMR (400MHz, CDCl3): δ7.35–7.31(m,1H),7.28(d,J=4.7Hz,4H),7.27–7.23(m,2H),7.23–7.14(m,5H),7.13–7.11 (m,2H),6.80–6.78(m,1H),6.76(dd,J=7.7,5.4Hz,4H),5.72(dd,J=22.7, 8.3Hz,1H),5.08–4.99(m,2H),4.69–4.59(m,1H),4.35–4.30(m,1H),3.73 (dd,J=4.5,3.7Hz,6H),3.65–3.44(m,2H),3.36–3.20(m,3H),1.86–1.81( m,1H),1.70(s,1H),0.80(d,J=13.1Hz,9H),-0.02(dd,J=14.9,4.2Hz,6H).
[0129] 2.5 Preparation of Intermediate 2-5
[0130] Compound 2-4 (10.43 mmol, 7.56 g) was placed in a clean, dry reaction flask, and 100 mL of methanol was added. Palladium on carbon (wet basis, 10% Pd / C) (10% wt, 750.0 mg) was then added under hydrogen at room temperature. Stirring was continued at room temperature for 12 hours. After the reaction, the palladium on carbon was removed by filtration, and the filtrate was concentrated to obtain the crude product, compound 2-5 (6.0 g, 10.22 mmol, 98% yield), as a white solid. This was used directly in the next reaction without purification. Compound 2-5 molecular formula: C 34 H 46 O5N2Si, molecular weight: 590.3, LC-MS measured: 591.6 (M+H).
[0131] 2.6 Preparation of Intermediate 2-6
[0132] Compound 5-(((2R,3R,4R,5R,6R)-3-acetylamino-4,5-diacetoxy-6-(acetoxymethyl)tetrahydro-2H-pyran-2-yl)oxy)pentanoic acid (commercially available, purchased from Noganlin Biopharmaceutical Technology (Suzhou) Co., Ltd.) (2.06 g, 4.62 mmol) was placed in a clean dry reaction bottle, 100 mL of dichloromethane was added, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 equiv, 6.93 mmol, 2.63 g) was added at room temperature and stirred for ten minutes. Subsequently, compound 2-5 (1.1 equiv, 5.08 mmol, 3.0 g) and N,N-diisopropylethylamine (3.0 equiv, 13.86 mmol, 17.91 g) were added to the reaction system, and stirring was continued at room temperature for 1 hour. After the reaction, 150 mL of dichloromethane was added to the reaction solution, and the mixture was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was separated and purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1-10 / 1) to obtain a white solid compound 2-6 (3.58 g, 3.51 mmol, 76% yield). Compound 2-6 molecular formula: C 53 H 73 O 15 N3Si, molecular weight: 1019.3, LC-MS measured: 1018.3 (MH).
[0133] 2.7 Preparation of Intermediate 2-7
[0134] Compound 2-6 (3.51 mmol, 3.58 g) was placed in a clean, dry reaction flask, 50 mL of pyridine was added, and triethylamine hydrofluoride (5.0 equiv, 17.55 mmol, 2.97 g) was added at room temperature, followed by stirring at room temperature for 12 hours. After the reaction, 100 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with 100 mL of saturated sodium bicarbonate solution and 100 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The crude product was separated and purified by silica gel column chromatography (dichloromethane / methanol = 50 / 1-10 / 1) to obtain compound 2-7 (2.4 g, 2.65 mmol, 76% yield) as a light yellow oil. Compound 2-7 molecular formula: C 47 H 59 O 15N3, molecular weight: 905.3, LC-MS measured: 904.4 (MH). 1H NMR (400 MHz, CDCl3): δ7.30 (dd, J = 4.2, 1.9 Hz, 1H), 7.29–7.25 (m, 5H), 7.19–7.15 (m, 4H), 6.85–6.81 (m, 4H), 5.40–5.34 (m, 1H), 5.30 (s,1H),5.26–5.19(m,1H),5.13(ddd,J=14.5,10.9,3.3Hz,1H),4.85–4.78(m,1H),4.75–4.71(m, 1H),4.68–4.61(m,1H),4.50(d,J=11.5Hz,1H),4.18–4.11(m,2H),4.06–3.97(m,1H),3.90(dt,J=1 0.6,6.8Hz,2H),3.80(s,6H),3.67–3.46(m,4H),3.25–3.19(m,2H),2.34–2.23(m,1H),2.17–2.15 (m,3H),2.10–2.03(m,5H),1.98(dt,J=12.9,2.4Hz,4H),1.76–1.61(m,4H),1.37(t,J=7.3Hz,3H).
[0135] 2.8 Preparation of Compound I-1-7
[0136] Compound 2-7 (2.65 mmol, 2.4 g) was placed in a clean, dry reaction flask and 50 mL of anhydrous dichloromethane (commercially available from Shanghai Titan Technology Co., Ltd.) was added. Under argon protection at room temperature, 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (2.0 equiv, 5.3 mmol, 1.6 g) and 4,5-dicyanimidazole (1.5 equiv, 3.97 mmol, 470.0 mg) were added and stirred at room temperature for one hour. After the reaction, 50 mL of dichloromethane was added to the reaction solution and washed with 100 mL of saturated sodium bicarbonate solution. The organic phase was dried, filtered and concentrated. The crude product was purified by C18 reverse phase column (specification: 30 μm; Commercially available, purchased from Shanghai Boyun Biotechnology Co., Ltd.) (MeCN:H2O=75%:25%) to prepare white solid I-1-7 (2.03 g, 1.84 mmol, 70% yield). Compound I-1-7 molecular formula: C 56 H 76 O 15 N6P, molecular weight: 1105.5, LC-MS measured: 1128.4 (M+Na). 1H NMR (400MHz, DMSO-d6): δ8.12–8.06(m,1H),7.78(dd,J=9.1,2.0Hz,1H),7.35–7.28(m,4H),7.23–7.17(m,5H),6.88(d,J=7.5Hz,4H),5.21(d,J =3.3Hz,1H),4.97(dd,J=11.2,3.0Hz,1H),4.86–4.75(m,1H),4.52(s,1 H),4.47(d,J=8.5Hz,1H),4.04–3.98(m,3H),3.91–3.83(m,1H),3.74(s ,6H),3.70–3.60(m,3H),3.58–3.47(m,3H),3.39(t,J=11.7Hz,2H),3.3 1(d,J=4.1Hz,1H),3.19(qd,J=8.7,3.8Hz,1H),3.02(dt,J=19.9,6.8Hz ,1H),2.78–2.70(m,1H),2.60(td,J=5.8,1.8Hz,1H),2.09(s,5H),1.98 (s,4H),1.89(s,3H),1.73(s,3H),1.44(s,4H),1.20–0.88(m,14H).31P NMR (162MHz, DMSO-d6): δ148.22 (s), 146.82 (t, J = 35.8Hz).
[0137] 2. Preparation of Compound SA102
[0138] 2.1 Preparation of Intermediate 1-1
[0139] Compound (R)-(+)-N-benzyl-3-hydroxypyrrolidine (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) (16.9 mmol, 3.0 g) and imidazole (3.0 equiv, 50.7 mmol, 3.45 g) were placed in a clean, dry reaction flask, 50 mL of acetonitrile was added, and tert-butyldimethylsilyl chloride (1.3 equiv, 21.9 mmol, 3.31 g) was slowly added at room temperature. Stirring was then continued at room temperature for 12 hours. After the reaction, 100 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with 100 mL of saturated sodium bicarbonate solution and 100 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The crude product was separated and purified by silica gel column chromatography (gradient elution: petroleum ether / ethyl acetate = 20 / 1-5 / 1) to obtain compound 1-1 (4.9 g, 16.8 mmol, 99% yield) as a colorless oil. Compound 1-1 Molecular formula: C 17 H 29ONSi, molecular weight: 291.2, LC-MS found 292.4 (M+H).
[0140] 2.2 Preparation of intermediate 1-2
[0141] Compound 1-1 (16.8 mmol, 4.9 g) was placed in a clean, dry reaction flask, and 100 mL of methanol was added. Palladium on carbon (wet basis, 10% Pd / C) (10% wt, 490.0 mg) was then added under hydrogen at room temperature. Stirring was continued at room temperature for 12 hours. After the reaction, the palladium on carbon was removed by filtration, and the filtrate was concentrated to obtain the crude product, compound 1-2 (3.31 g, 16.5 mmol, 98% yield), as a white solid. This was used directly in the next reaction without purification. Compound 1-2 Molecular formula: C 10 H 23 ONSi, molecular weight: 201.1, LC-MS found 202.3 (M+H).
[0142] 2.3 Preparation of intermediate 1-3
[0143] Compound N-benzyloxycarbonyl-L-serine (commercially available, purchased from Shanghai Titan Technology Co., Ltd.) (15.0 mmol, 3.58 g) was placed in a clean dry reaction bottle, 100 mL of dichloromethane was added, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 equiv, 22.5 mmol, 8.53 g), compound 1-2 (1.1 equiv, 16.5 mmol, 3.31 g) and N,N-diisopropylethylamine (3.0 equiv, 45.0 mmol, 5.78 g) were added at room temperature, followed by stirring at room temperature for 1 hour. After the reaction, 150 mL of dichloromethane was added to the reaction solution, and the mixture was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was separated and purified by silica gel column chromatography (gradient elution: petroleum ether / ethyl acetate = 10 / 1-1 / 3) to obtain a white solid compound 1-3 (4.5 g, 10.65 mmol, 63% two-step yield). Compound 1-3 molecular formula: C 21 H 34 O5N2Si, molecular weight: 422.2, LC-MS found 423.3 (M+H). 1H NMR (400MHz, CDCl3): δ7.35–7.29(m,5H),5.96(dd,J=14.3,8.3Hz,1H),5.10(s,2H),4.61–4.40(m,2H),3.85–3.68(m,2H),3.65–3.4 9(m,2H),3.41(d,J=12.7Hz,1H),3.31(s,1H),1.95(qdd,J=15.0,11.8,5.3Hz,2H),1.77(s,1H),0.86(s,9H),0.06(d,J=3.1Hz,6H).
[0144] 2.4 Preparation of Intermediates 1-4
[0145] Compound 1-3 (10.65 mmol, 4.5 g) was placed in a clean, dry reaction flask, 100 mL of pyridine was added, and 4,4'-bismethoxytrityl chloride (1.2 equiv, 12.78 mmol, 4.32 g) was added at room temperature, followed by stirring at room temperature for 12 hours. After the reaction, 150 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The crude product was separated and purified by silica gel column chromatography (gradient elution: petroleum ether / ethyl acetate = 20 / 1-1 / 1) to obtain compound 1-4 (7.56 g, 10.43 mmol, 98% yield) as a light yellow oil. Compound 1-4 molecular formula: C 42 H 52 O7N2Si, molecular weight: 724.3, LC-MS found 747.4 (M+Na). 1 HNMR (400MHz, CDCl3): δ7.35–7.31(m,1H),7.28(d,J=4.7Hz,4H),7.27–7.23(m,2H),7.23–7.14(m,5H),7 .13–7.11(m,2H),6.80–6.78(m,1H),6.76(dd,J=7.7,5.4Hz,4H),5.72(dd,J=22.7,8.3Hz,1H),5.08–4.99 (m,2H),4.69–4.59(m,1H),4.35–4.30(m,1H),3.73(dd,J=4.5,3.7Hz,6H),3.65–3.44(m,2H),3.36– 3.20(m,3H),1.86–1.81(m,1H),1.70(s,1H),0.80(d,J=13.1Hz,9H),-0.02(dd,J=14.9,4.2Hz,6H).
[0146] 2.5 Preparation of Intermediate 1-5
[0147] Compound 1-4 (10.43 mmol, 7.56 g) was placed in a clean, dry reaction flask, and 100 mL of methanol was added. Palladium on carbon (wet basis, 10% Pd / C) (10% wt, 750.0 mg) was then added under hydrogen at room temperature. Stirring was continued at room temperature for 12 hours. After the reaction, the palladium on carbon was removed by filtration, and the filtrate was concentrated to obtain the crude product, compound 1-5 (6.0 g, 10.22 mmol, 98% yield), as a white solid. This was used directly in the next reaction without purification. Compound 1-5 Molecular formula: C 34 H 46 O5N2Si, molecular weight: 590.3, LC-MS found 591.6 (M+H).
[0148] 2.6 Preparation of Intermediates 1-6
[0149] Compound 1-5 (10.22 mmol, 6.0 g) was placed in a clean, dry reaction flask and added with 100 mL of dichloromethane. 4-Dimethylaminopyridine (30 mol%, 3.07 mmol, 374.6 mg) and N,N-diisopropylethylamine (3.0 equiv, 30.66 mmol, 3.96 g) were then added at room temperature. Adipic anhydride (1.5 equiv, 15.33 mmol, 1.96 g) was then added to the reaction system and stirred at room temperature for 4 hours. After the reaction, the reaction solution was directly concentrated, and the resulting crude product was purified by silica gel column chromatography (gradient elution: dichloromethane / methanol = 50 / 1-8 / 1) to obtain compound 1-6 (5.28 g, 7.36 mmol, 72% yield) as a white solid. Compound 1-6 Molecular formula: C 40 H 54 O8N2Si, molecular weight: 718.3, LC-MS found 717.3 (MH).
[0150] 2.7 Preparation of Intermediates 1-8
[0151] Compound 1-6 (7.36 mmol, 5.28 g) was placed in a clean, dry reaction bottle, 100 mL of dichloromethane was added, and benzotriazole-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.5 equiv, 11.04 mmol, 4.19 g), N,N-diisopropylethylamine (3.0 equiv, 22.08 mmol, 2.85 g) and compound 1-7 (commercially available, purchased from Tianjin WuXi AppTec New Drug Development Co., Ltd.) (1.1 equiv, 8.1 mmol, 4.31 g) were added at room temperature, and stirring was continued at room temperature for 1 hour. After the reaction, 150 mL of dichloromethane was added to the reaction solution, and the mixture was washed with 150 mL of saturated sodium bicarbonate solution and 150 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was separated and purified by silica gel column chromatography (gradient elution: dichloromethane / methanol = 50 / 1-10 / 1) to obtain a light yellow solid compound 1-8 (6.75 g, 6.04 mmol, 82% yield). Compound 1-8 molecular formula: C 58 H 82 O 16 N4Si, molecular weight: 1118.5, LC-MS found 1117.3 (MH).
[0152] 2.8 Preparation of Intermediates 1-9
[0153] Compound 1-8 (6.04 mmol, 6.75 g) was placed in a clean, dry reaction flask, and 50 mL of tetrahydrofuran was added. Tetrabutylammonium fluoride (1.0 M in THF) (2.0 equiv, 12.08 mmol, 12.08 mL) was then added at room temperature, and stirring continued at room temperature for 2 hours. After the reaction, 100 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with 100 mL of saturated sodium bicarbonate solution and 100 mL of saturated brine. The organic phase was dried, filtered, and concentrated. The resulting crude product was separated and purified by silica gel column chromatography (gradient elution: dichloromethane / methanol = 50 / 1-8 / 1) to obtain a light yellow solid compound 1-9 (5.22 g, 5.19 mmol, 86% yield). Compound 1-9 molecular formula: C 52 H 68 O 16 N4, molecular weight: 1004.4, LC-MS found 1003.3 (MH).
[0154] 2.9 Preparation of compound SA102
[0155] Compound 1-9 (5.19 mmol, 5.22 g) was placed in a clean, dry reaction flask and 50 mL of anhydrous dichloromethane was added. Under argon protection at room temperature, 2-cyanoethyl N,N,N',N'-tetraisopropylphosphorodiamidite (2.0 equiv, 10.38 mmol, 3.13 g) and 4,5-dicyanimidazole (1.5 equiv, 7.79 mmol, 920.2 mg) were added and stirred at room temperature for one hour. After the reaction, 50 mL of dichloromethane was added to the reaction mixture, which was then washed with 100 mL of saturated sodium bicarbonate solution. The organic phase was dried, filtered, and concentrated. The resulting crude product was purified by chromatography on a C18 reverse-phase column (specification: 30 μm; Commercially available, purchased from Shanghai Boyun Biotechnology Co., Ltd.) (MeCN:H2O=75%:25%) to prepare white solid SA102 (4.44 g, 3.68 mmol, 71% yield). Compound SA102 molecular formula: C 61 H 85 O 17 N6P, molecular weight: 1204.5, LC-MS found 1227.3 (M+Na). 1 HNMR (400MHz, DMSO-d6): δ8.10(q,J=8.3Hz,1H),7.80(d,J=9.2Hz,1H),7.68(d d,J=8.8,4.9Hz,1H),7.35–7.28(m,4H),7.20(ddd,J=11.2,6.7,2.2Hz,5H),6.8 9–6.87(m,4H),5.21(d,J=3.3Hz,1H),4.96(dd,J=11.2,3.4Hz,1H),4.85–4.74( m,1H),4.48(d,J=8.5Hz,2H),4.04–3.99(m,3H),3.87(dd,J=20.0,8.9Hz,1H),3 .74(s,6H),3.72–3.67(m,2H),3.63–3.46(m,4H),3.44–3.38(m,2H),3.18(qd,J =8.8,4.6Hz,2H),3.06–2.97(m,3H),2.74(ddd,J=16.6,11.8,5.9Hz,1H),2.61( td,J=5.8,1.8Hz,1H),2.10(s,5H),1.99(s,6H),1.89(s,3H),1.76(s,3H),1.46 –1.33(m,8H),1.24–1.09(m,12H),1.06(d,J=6.7Hz,1H),1.00(d,J=6.7Hz,1H). 31P NMR (162MHz, DMSO-d6): δ147.07 (s), 146.74 (t, J = 32.0Hz).
[0156] Example 3 Synthesis of Ugo monomer and Tgo monomer
[0157] 3.1. The synthesis route of Ugo monomer refers to Example 5 of the applicant's patent application No. 202310436173.7. The specific synthesis method is as follows:
[0158] (1) Compound 1-4 (9.99 g, 30.8 mmol), compound U-1 (commercially available, purchased from Shanghai Haohong Biopharmaceutical Technology Co., Ltd.) (9.33 g, 43.1 mmol, 1.4 equiv) and triphenylphosphine (16.6 g, 63.2 mmol, 2.0 equiv) were dissolved in dry tetrahydrofuran (350.0 mL) in an ice-water bath, and diisopropyl azodicarboxylate (13.1 g, 64.7 mmol, 12.6 mL, 2.1 equiv) was then added dropwise to the reaction system. The reaction solution was then stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was extracted three times with saturated sodium bicarbonate solution and ethyl acetate, the organic phases were combined and dried, and the crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate 10:1 to 8:1) to obtain a white solid compound 3-1 (16.1 g, reaction yield 99%). 1 H NMR data: (400 MHz, DMSO-d6) δ 7.89-7.74 (m, 4H), 7.56-7.53 (m, 2H), 7.33-7.29 (m, 5H), 5.80-5.73 (m, 1H), 4.46-4.38 (m, 2H), 4.00-3.91 (m, 2H), 3.60-3.50 (m, 1H), 3.49-3.43 (m, 2H) 2.17-1.98 (m, 1H), 1.13 (s, 3H), 0.83 (s, 9H), 0.01 (d, J = 6.0 Hz, 6H). Mass spectrometric identification of compound 3-1 (C 29 H 38 N2O5Si, molecular weight 522.1, [M+H] = 523.2).
[0159] (2) Compound 3-1 (8.05 g, 15.4 mmol) was dissolved in methanol (160.0 mL) at room temperature, and then sodium methoxide (2.77 g, 15.4 mmol, 30% purity, 1.0 equiv) was slowly added to the reaction system. The reaction solution was then stirred at room temperature for 12 hours. After the reaction was completed, the solvent methanol was removed by distillation under reduced pressure, and the remaining system was extracted with 1M hydrochloric acid solution and ethyl acetate three times. The organic phases were combined and dried by spin drying. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate 10:1 to 0:1) to obtain white solid compound 3-2 (6.1 g, reaction yield 94%). 1 H NMR data: (400 MHz, DMSO-d6) δ 11.1 (s, 1H), 7.48 (d, J = 8.0 Hz, 1H), 7.30-7.24 (m, 5H), 5.47-5.44 (m, 1H), 4.45-4.35 (m, 2H), 3.98-3.94 (m, 1H), 3.79-3.78 (m, 1H), 3.63-3.57 (m, 1H), 3.38-3.35 (m, 2H), 2.04-1.95 (m, 1H), 1.10 (s, 3H), 0.83 (s, 9H), 0.01 (d, J = 6.0 Hz, 6H). Mass spectrometric identification of compound 3-2 (C 22 H 34 N2O4Si, molecular weight 418.1, [M+H] = 418.2).
[0160] (3) Compound 3-2 (4.0 g, 9.56 mmol) was dissolved in dichloromethane (30.0 mL) at -70 °C, and then boron trichloride (1.0 M in DCM, 66.9 mL, 7.0 equiv) was slowly added to the reaction system. The reaction solution was then stirred at -70 °C for 3 hours. After the reaction was completed, the reaction was quenched with triethylamine (5.0 mL) and methanol (30.0 mL). The remaining system was extracted with water and dichloromethane for 3 times. The organic phases were combined and dried, and the crude product was prepared using a C18 reverse phase column to obtain a white solid compound 3-3 (0.7 g, reaction yield 33%). 1 H NMR data: (400 MHz, DMSO-d6) δ7.54 (d, J = 8.0 Hz, 1H), 5.51 (d, J = 7.6 Hz, 1H), 3.88-3.84 (m, 1H), 3.72-3.70 (m, 1H), 3.61-3.59 (m, 2H), 1.75-1.68 (m, 1H), 1.09 (d, J = 6.4 Hz, 3H). Mass spectrometric identification of compound 3-3 (C9H 14N2O4, molecular weight 214.1, [M+H] = 215.2).
[0161] (4) Compound 3-1 (0.4 g, 1.87 mmol) was dissolved in pyridine (4.0 mL) at room temperature, and 4,4'-bismethoxytrityl chloride (949.0 mg, 2.8 mmol, 1.5 equiv) was added to the reaction system under ice-water bath conditions. The reaction solution was then stirred at room temperature for 2 hours. After the reaction was completed, the solvent pyridine was removed by distillation under reduced pressure, and the remaining system was extracted with saturated sodium bicarbonate solution and ethyl acetate three times. The organic phases were combined and dried by spin drying. The crude product was separated and purified by silica gel column chromatography (petroleum ether / ethyl acetate 4:1 to 0:1) to obtain a white solid compound 3-4 (0.7 g, reaction yield 70%). 1 H NMR data: (400 MHz, DMSO-d6) δ 11.3 (s, 1H), 7.37 (d, J = 8.0 Hz, 1H), 7.33-7.29 (m, 4H), 7.20-7.17 (m, 5H), 6.86-6.83 (m, 4H), 5.40 (d, J = 8.0 Hz, 1H), 4.61 (d, J = 4.8 Hz, 2H), 3.83-3.79 (m, 2H), 3.72 (s, 6H), 3.71-3.68 (m, 1H), 3.08-2.90 (m, 2H), 1.90 (s, 1H), 1.01 (d, J = 6.4 Hz, 3H). Mass spectrometric identification of compound 3-4 (C 30 H 32 N2O6, molecular weight 516.1, [M+H] = 517.4).
[0162] (5) Compound 3-4 (1.2 g, 2.32 mmol) was dissolved in dichloromethane (12.0 mL) under nitrogen conditions at room temperature, and 4,5-dicyanoimidazole (357.0 mg, 3.02 mmol, 1.3 equiv) and bis(diisopropylamino)(2-cyanoethoxy)phosphine (1.05 g, 3.48 mmol, 1.5 equiv) were added to the reaction system respectively. The reaction solution was then stirred at room temperature for 2 hours. After the reaction was completed, the reaction solution was dissolved in methyl tert-butyl ether (10.0 mL) and 1% sodium hydroxide solution (10.0 mL), and continued to stir at room temperature for 0.5 hours. The remaining system was extracted with ethyl acetate for 3 times, and the organic phases were combined and dried by rotation. The crude product was prepared by C18 reverse phase column to obtain white solid compound SA000016 (1.2 g, reaction yield 71%). Compound SA000016 1H NMR data: (400 MHz, CD3CN) δ9.39 (s, 1H), 7.39-7.24 (m, 10H), 6.85-6.81 (m, 4H), 5.43-5.39 (m, 1H), 4.21-4.18 (m, 1H), 3.86-3.77 (m, 1H), 3.75 (s, 6H), 3.56-3.53 (m, 5H), 3.28-3.05 (m, 2H), 2.62-2.61 (m, 2H), 2.22-2.19 (m, 2H), 1.22-1.07 (m, 15H). 31 P NMR data: (400MHz, CD3CN) δ147.6, 146.5. Mass spectrometry identification of compound SA000016 (C 39 H 49 N4O7P, molecular weight 716.1, [M+H] = 717.5).
[0163] 3.2. Synthesis of Tgo monomer
[0164] According to the synthesis method of Example Ugo, a white solid Tgo (4.8 g, 6.6 mmol, 74% yield) was prepared. The molecular formula of compound Tgo is: C 40 H 51 O7N4P, molecular weight: 730.3, LC-MS found 753.4 (M+Na). 1 H NMR (400MHz, DMSO-d6): δ11.75(d,J=215.2Hz,1H),7.90(d,J=4.6Hz,1H),7.23–7.22(m,4H),7.20–7 .14(m,1H),7.09(td,J=7.1,3.5Hz,4H),7.23–7.22(m,4H),4.23(dd,J=13.9,5.2Hz,1H),4.14–3.99( m,2H),3.71(s,6H),3.59–3.53(m,1H),3.51–3.43(m,2H),3.13(td,J=9.4,5.5Hz,1H),3.05–2.93(m ,1H),2.82(dt,J=13.5,6.8Hz,1H),2.73(t,J=5.9Hz,1H),2.65(t,J=5.8Hz,1H),1.26–0.98(m,19H). 31 P NMR (162MHz, DMSO-d6): δ147.0,146.6.
[0165] Example 4 Preparation of siRNA Conjugates
[0166] Using the solid-phase phosphoramidite method, compound SA51, SA102, or L96, prepared in the above steps, was used as the starting cycle to link nucleoside monomers one by one in the 3'-5' direction according to the nucleotide sequence. Each linking step involved four steps: deprotection, coupling, capping, and oxidation or sulfurization. The same synthesis conditions were used for both the sense and antisense strands.
[0167] Instruments: Biolytic Dr. Oligo 48 solid phase synthesizer, Biocomma Embed CPG Frits universal synthesis column DS0200, Biocomma 96-well plate desalting column DC189650 (80 mg). Table 3 shows the reagents used in the synthesis of siRNA conjugates.
[0168] Table 3
[0169] The synthesis conditions are as follows:
[0170] The nucleoside monomer was provided as a 0.05 M acetonitrile solution. The deprotection reaction conditions for each step were the same, ie, the temperature was 25° C., the reaction time was 3 minutes, the deprotection reagent was DCA, and the injection volume was 180 μL.
[0171] The coupling reaction conditions were identical for each step, including a temperature of 25°C and a reaction time of 3 minutes. The injection volume for the nucleoside monomer was 90 μL, and the injection volume for the catalyst ACT was 110 μL.
[0172] The capping conditions were identical for each step, including a temperature of 25°C and a reaction time of 2 minutes. The capping reagent solution was a 1:1 molar ratio of CapA to CapB. The capping reagent injection volume was 180 μL.
[0173] The oxidation reaction conditions in each step were the same, including a temperature of 25°C, a reaction time of 3 minutes, and an injection volume of 180 μL of the oxidizing reagent OXD.
[0174] The reaction conditions for each sulfurization step were identical, including a temperature of 25°C, a reaction time of 4 minutes, and a sulfurization reagent of 0.05 M PADS in pyridine-acetonitrile. The injection volume of the sulfurization reagent was 180 μL.
[0175] After the last nucleoside monomer is connected, the nucleic acid sequence connected to the solid phase support is cut, deprotected, purified, desalted, and then freeze-dried to obtain the sense chain and antisense chain, wherein:
[0176] Cleavage and deprotection conditions were as follows: The synthesized nucleotide sequence linked to the vector was added to a 3:1 mixture of ammonia and ethanol to a volume of 0.8 mL. The mixture was reacted at 50°C for 15 h, the remaining vector was removed by filtration, and the supernatant was concentrated to dryness in vacuo.
[0177] Purification and desalting conditions are as follows: Desalting is performed using a C18 reverse phase column. Specific conditions include:
[0178] (1) Sample preparation
[0179] 0.1 M TEAA (triethylamine acetate) was added to the oligonucleotide sample to a volume of 0.8 mL.
[0180] (2) Activation of 96-well plates
[0181] Activation: 0.8 mL of acetonitrile was passed through each well of a 96-well plate for activation;
[0182] Equilibration: 96-well plates were equilibrated with 0.8 mL of TEAA (pH 7.0) solution.
[0183] (3) The purification process is carried out in the following order:
[0184] 0.8 mL of the solution containing the oligonucleotide was passed through a desalting column;
[0185] Wash the 96-well plate twice with 0.8 mL of 6.5% ammonia to remove failed sequences;
[0186] Rinse the 96-well plate twice with 0.8 mL of deionized water to remove salt;
[0187] The 96-well plate was washed three times with 0.8 mL of 3% trifluoroacetic acid to remove DMT, and the adsorbed layer was observed to turn orange-red;
[0188] Rinse the 96-well plate with 0.8 mL of 0.1 M TEAA;
[0189] Rinse the 96-well plate twice with 0.8 mL of deionized water to remove trifluoroacetic acid and residual salts;
[0190] Elution was performed with 0.6 mL of 20% acetonitrile and the resulting product was collected and lyophilized.
[0191] The purity and molecular weight of the sense and antisense strands were determined using a Waters Acquity UPLC-LTQ LCMS (ACQUITY UPLC BEH C18 column). The observed values were consistent with the theoretical values, indicating that the synthesized sense and antisense strands were conjugated with groups at the 3' and / or 5' ends.
[0192] Annealing is performed as follows: Dissolve the synthesized sense and antisense strands separately in water for injection to prepare a 0.1 mg / mL to 40 mg / mL solution. Use a concentration meter to calibrate the mixture at an equal molar ratio. Heat at 90°C for 5 minutes, then slowly cool naturally to allow hydrogen bonding to form a double-stranded structure. Samples are then collected and sent for SEC purity testing. The double-stranded sample is lyophilized.
[0193] Example 5: Screening of single-concentration inhibitory activity of siRNA against human AGT in Hep3B cells
[0194] The effects of AGT-targeting siRNA on AGT mRNA expression were tested in vitro. Hep3B cells were cultured in DMEM high-glucose medium supplemented with 10% fetal bovine serum at 37°C and 5% CO2. For transfection, Hep3B cells were seeded in 96-well plates at a density of 20,000 cells per well in 100 μL of culture medium.
[0195] According to the product manual, siRNA was transfected using Lipofectamine RNAiMAX (ThermoFisher, 13778150) with a final concentration of 10 nM. After 24 hours of treatment, RNA was isolated from cells using a cell RNA extraction kit (Zhiang Bio, MNTR / FX96) and reverse transcription kit (Takara PrimeScript TM II 1st Strand cDNA Synthesis Kit, 6210A) for reverse transcription, and quantitative real-time PCR detection was performed using a qPCR reaction kit (ThermoFisher TaqMan Fast Advanced Master Mix, 4444964) to determine the mRNA level of AGT.
[0196] Target gene AGT primers and probes:
[0197] Forward primer: GTATGTACACCCGGTCACC (SEQ ID NO: 219);
[0198] Reverse primer: GTTGTTCTGGGTACTACAGCA (SEQ ID NO: 220);
[0199] Probe: CATCCTCTGCCTCCTGGCCTG (SEQ ID NO: 221);
[0200] Primers and probes for the internal reference gene β-actin:
[0201] Forward primer: TGCACCACCAACTGCTTAGC (SEQ ID NO: 222);
[0202] Reverse primer: ACTGTGGTCATGAGTCCTTCCA (SEQ ID NO: 223);
[0203] Probe: TCATCCATGACAACTTTGGTA (SEQ ID NO: 224);
[0204] The results are expressed as the remaining percentage relative to the AGT mRNA expression of cells not treated with siRNA (which is 100%). The smaller the remaining percentage, the higher the inhibitory activity of siRNA. The results are shown in Table 4.
[0205] Table 4
[0206] Example 6 Inhibition of human AGT by siRNA in Hep3B cells, double concentration activity
[0207] siRNAs showing an in vitro inhibitory effect of 65% or higher listed in Table 4 were screened in Hep3B cells at two concentrations (10 nM, 0.1 nM).
[0208] Hep3B cells were cultured in DMEM high-glucose medium supplemented with 10% fetal bovine serum at 37°C and 5% CO2. 24 h before transfection, Hep3B cells were seeded in 96-well plates at a density of 10,000 cells per well in 100 μL of culture medium per well.
[0209] According to the product manual, siRNA was transfected using Lipofectamine RNAiMAX (ThermoFisher, 13778150) with a final concentration of 10 nM and 1 nM. After 24 hours of treatment, TaqMan TM Fast Advanced Cells-to-CT TM Kit (ThermoFisher, A35378) was used for quantitative real-time PCR to determine the mRNA level of AGT, wherein the primers and probe for the target gene AGT and the primers and probe for the internal reference gene β-actin were the same as those in Example 5.
[0210] The results are expressed as the remaining percentage relative to the AGT mRNA expression of cells not treated with siRNA (which is 100%). The smaller the remaining percentage, the higher the inhibitory activity of siRNA. The results are shown in Table 5.
[0211] Table 5
[0212] Example 7 Activity of the conjugate tested in mice
[0213] At least 14 days before the administration of the conjugate, humanized AGT-expressing mice were constructed in female Bab / C mice aged six to eight weeks by high-pressure tail vein injection. As previously described, 2 μg of plasmid containing the AGT mRNA sequence was injected into the mice through the tail vein within 5-7 seconds to generate AGT-SEAP model mice (Zhang G et al., "High levels of foreign gene expression in hepatocytes after tail vein injection of naked plasmid DNA." Human Gene Therapy 1999 Vol. 10, p1735-1737.). The inhibition of AGT expression by the AGT siRNA conjugate leads to the inhibition of SEAP expression. One day before administration, blood was collected by orbital bleeding and serum was collected with Phospha-Light according to the product instructions. TM SEAP reporter gene analysis system (Invitrogen) was used to measure the SEAP expression level in serum, and mice were grouped according to the average SEAP level. The experimental group of mice was given the conjugate, and the vehicle group of mice was given phosphate buffered saline (PBS). The conjugate was administered subcutaneously at a dose of 1 mg / kg per mouse. Blood was collected again 7 days after administration, and serum was collected and analyzed using Phospha-Light according to the product instructions. TM SEAP expression levels in serum were measured using the SEAP Reporter Gene Assay System (Invitrogen). The SEAP level in each animal after dosing was divided by the SEAP level before dosing to determine the "normalized to pre-treatment" expression ratio.
[0214] The results are expressed as the residual expression level of serum SEAP before and after administration of each group (the vehicle group is 100%). The sequences of the conjugates used for injection are shown in Table 6, and the preparation methods are shown in Example 4. The relative residual expression level results are shown in Figure 1. Compared with the positive compound SD003660, the conjugates SD003664, SD003665, SD003666, SD003667, SD003672, SD003674, and SD003676 initially showed activity comparable to that of the positive compound.
[0215] Table 6
[0216] in,
[0217] The structure of L96 is:
[0218] Example 8 Activity of unconjugated siRNA in Hep3B cells, IC50 test in vitro
[0219] In this example, the previously selected siRNA was modified and synthesized. The synthesis method is shown in Example 1 (sequence in Table 7). IC50 in vitro screening was carried out in Hep3B cells using 8 concentrations (starting from 10 nM and 3-fold dilution, a total of 8 concentration points).
[0220] The effects of AGT-targeting siRNA on AGT mRNA expression were tested in vitro. Hep3B cells were cultured in DMEM high-glucose medium supplemented with 10% fetal bovine serum at 37°C and 5% CO2. For transfection, Hep3B cells were seeded in 96-well plates at a density of 20,000 cells per well in 100 μL of culture medium.
[0221] siRNA was transfected using Lipofectamine RNAiMAX (ThermoFisher, 13778150) according to the product manual. siRNA was diluted 2.5 times to 0.000839 at 8 nM for transfection. The siRNA sequences are shown in Table 7. 24 hours after transfection, RNA was isolated from cells using a tissue cell extraction kit (Zhiang Biotechnology, MNTR / FX96) and reverse transcription kit (Takara PrimeScript TM Reverse transcription was performed using the II 1st Strand cDNA Synthesis Kit, 6210A), and quantitative real-time PCR was performed using a qPCR reaction kit (ThermoFisher TaqMan Fast Advanced Master Mix, 4444964). The primers and probe for the target gene AGT and the internal reference gene β-actin were the same as in Example 5. The mRNA levels of AGT were measured at various concentrations, and the IC50 values were calculated. The test results are shown in Table 8. These conjugates all had excellent in vitro activity.
[0222] Table 7
[0223] Table 8
[0224] Example 9 Activity of the conjugate in Hep3B cells, IC50 in vitro test
[0225] In this example, the previously preferred siRNA was modified and synthesized. The synthesis method is shown in Example 4 (sequence is shown in Table 9). IC50 in vitro screening was carried out in Hep3B cells using 8 concentrations (starting from 10 nM and 3-fold dilution, a total of 8 concentration points). The experimental method was the same as in Example 8. The test results are shown in Table 10. These conjugates have good in vitro activity.
[0226] Table 9
[0227] SA102SA102SA102 means that three compounds SA102 are continuously conjugated to the 3' end of the sense chain. The conjugate structure is SA51SA51SA51 means that three compounds SA51 are continuously conjugated to the 3' end of the sense chain. The conjugate structure is
[0228] Table 10
[0229] Example 10 Activity of siRNAs with different sequences and chemical modifications in HDI mice
[0230] At least 14 days before the administration of the conjugate, humanized AGT-expressing mice were constructed in female Bab / C mice aged six to eight weeks by high-pressure tail vein injection. As previously described, 2 μg of plasmid containing the AGT mRNA sequence was injected into the mice through the tail vein within 5-7 seconds to generate AGT-SEAP model mice (Zhang G et al., "High levels of foreign gene expression in hepatocytes after tail vein injection of naked plasmid DNA." Human Gene Therapy 1999 Vol. 10, p1735-1737.). The inhibition of AGT expression by the AGT siRNA conjugate leads to the inhibition of SEAP expression. One day before administration, blood was collected by orbital bleeding and serum was collected with Phospha-Light according to the product instructions. TM SEAP reporter gene assay system (Invitrogen) was used to measure the SEAP expression level in serum, and mice were grouped according to the average SEAP level. The experimental group of mice was given the conjugate, and the vehicle group of mice was given phosphate buffered saline (PBS). Each mouse was subcutaneously administered with a dose of 1 mg / kg of the conjugate. Blood was collected again on days 6, 14, 21, and 28 after administration, and serum was collected and analyzed using Phospha-Light according to the product instructions. TMSEAP expression levels in serum were measured using the SEAP reporter gene assay system (Invitrogen). The SEAP level in each animal after dosing was divided by the SEAP level before dosing to determine the "normalized to pre-treatment" expression ratio.
[0231] The results are expressed as the residual expression level of serum SEAP before and after administration of each group (the vehicle group is 100%). The sequences of the conjugates used for injection are the same as those in Table 9. The relative residual expression levels are shown in Table 11. The results show that the activity of SD004457 is superior to that of SD004230 and SD004232.
[0232] Table 11
[0233] Example 11 Activity of siRNAs containing different chemical modifications in HDI mice
[0234] At least 14 days before the administration of the conjugate, humanized AGT-expressing mice were constructed in female Bab / C mice aged six to eight weeks by high-pressure tail vein injection. As previously described, 2 μg of plasmid containing the AGT mRNA sequence was injected into the mice through the tail vein within 5-7 seconds to generate AGT-SEAP model mice (Zhang G et al., "High levels of foreign gene expression in hepatocytes after tail vein injection of naked plasmid DNA." Human Gene Therapy 1999 Vol. 10, p1735-1737.). The inhibition of AGT expression by the AGT siRNA conjugate leads to the inhibition of SEAP expression. One day before administration, blood was collected by orbital bleeding and serum was collected with Phospha-Light according to the product instructions. TM SEAP reporter gene assay system (Invitrogen) was used to measure the SEAP expression level in serum, and mice were grouped according to the average SEAP level. The experimental group of mice was given the conjugate, and the vehicle group of mice was given phosphate buffered saline (PBS). Each mouse was given a dose of 1 mg / kg of the conjugate subcutaneously. Blood was collected again 7 days after administration, and serum was collected and analyzed using Phospha-Light according to the product instructions. TM SEAP expression levels in serum were measured using the SEAP reporter gene assay system (Invitrogen). The SEAP level in each animal after dosing was divided by the SEAP level before dosing to determine the "normalized to pre-treatment" expression ratio.
[0235] The results are expressed as the residual expression level of serum SEAP before and after administration of each group (the vehicle group is 100%). The conjugate sequences used for injection are the same as those in Table 9. The relative residual expression level results are shown in Figure 2. SD004457 has the best activity among these modified sequences.
[0236] Example 12 In vivo drug efficacy test in cynomolgus monkeys
[0237] In this example, siRNA was selected for conjugation synthesis, and the in vivo activity of the AGT siRNA conjugate was further evaluated in cynomolgus monkeys. Animals with uniform body weight and normal condition were randomly divided into groups of 3, and the conjugates SD004457, SD004230, and SD004232 listed in Table 9 were administered subcutaneously at a dose of 6 mg / kg per monkey. Blood was collected and serum was collected on days 7 and 0 before administration, and on days 7, 14, 21, 28, and 42 after administration. The AGT protein level in the serum was detected by ELISA. The results of the remaining percentage compared to the average level of AGT in the serum on days 7 and 0 before administration are shown in Figure 3. The activity of SD004457 in cynomolgus monkeys was significantly better than that of SD004230 and SD4232.
[0238] Example 13 In vivo drug efficacy testing in spontaneously hypertensive cynomolgus monkey models
[0239] In this example, siRNA was selected for conjugation synthesis, and the in vivo activity of the AGT siRNA conjugate was further evaluated in elderly cynomolgus monkeys with spontaneous hypertension. Animals with uniform body weight and normal condition were randomly divided into groups of 2, and the conjugate SD004457 in Table 9 was administered subcutaneously at a dose of 10 mg / kg per monkey. Blood pressure measurements of diastolic and systolic blood pressure were performed on days 7 before and 0 after administration, and on days 7, 14, 21, 28, 35, 42, and 49 after administration. Blood pressure was measured using the cuff method, and the systolic and diastolic blood pressure results at various points before and after administration are shown in Figures 4 and 5. The results show that SD004457 has a significant effect of lowering blood pressure in hypertensive cynomolgus monkeys.
[0240] The above detailed description of the present invention is intended to enable persons familiar with the art to understand the contents of the present invention and implement them. It does not limit the scope of protection of the present invention. Any equivalent changes or modifications made based on the spirit of the present invention should be included in the scope of protection of the present invention.
Claims
1. A double-stranded RNA comprising a sense strand and an antisense strand, Features: Each nucleotide in the double-stranded RNA is independently a modified or unmodified nucleotide, the positive strand includes a nucleotide sequence selected from one of the nucleotide sequences shown in SEQ ID NOs. 1 to 109 or a nucleotide sequence with no more than 3 base mutations in the above sequence, and the antisense strand includes a nucleotide sequence selected from one of the nucleotide sequences shown in SEQ ID NOs. 110 to 218 or a nucleotide sequence with no more than 5 base mutations in the above sequence.
2. The double-stranded RNA according to claim 1, Features: From 5' to 3', the base mutation of the sense strand is at the 3' end of its nucleotide sequence, and the base mutation of the antisense strand is at any one or more of the 5' end, the 2nd to 8th positions, and the last two positions of the 3' end of its nucleotide sequence.
3. The double-stranded RNA according to claim 1, Features: The modified nucleotides are 2'-methoxy modified nucleotides, 2'-fluoro modified nucleotides, 2'-O-CH 2 -CH 2 -O-CH 3 Modified nucleotides, 2'-O-CH 2 -CH=CH 2 Modified nucleotides, 2'-CH 2 -CH 2 -CH=CH 2 Modified nucleotides, 2'-deoxy nucleotides, 2'-methoxyethyl modified nucleotides, phosphorothioate modified nucleotides, VP modified nucleotides, LNA, ENA, cET BNA, UNA, GNA and One or more combinations of, wherein R1 is H, OH or CH 3 , Base is a natural nucleobase, a modified nucleobase, a universal base or an H atom.
4. The double-stranded RNA according to any one of claims 1 to 3, Features: One or more nucleotides in the sense strand or the antisense strand are modified nucleotides.
5. The double-stranded RNA according to any one of claims 1 to 3, Features: From 5' to 3', the nucleotides at positions 7, 8 and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides; from 5' to 3', the nucleotides at positions 2, 6, 14 and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides; at least one of the following connections between nucleotides in the double-stranded RNA is a phosphorothioate connection: The connection between the first nucleotide and the second nucleotide at the 5' end of the sense strand; The connection between the second nucleotide and the third nucleotide at the 5' end of the sense strand; The connection between the first nucleotide and the second nucleotide at the 3' end of the sense strand; The connection between the second nucleotide and the third nucleotide at the 3' end of the sense strand; The connection between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; The connection between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; The connection between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
6. The double-stranded RNA according to any one of claims 1 to 3, Features: From 5' to 3', the nucleotides at positions 7, 9 and 11 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides; from 5' to 3', the nucleotides at positions 2, 14 and 16 of the antisense strand are 2'-fluoro-modified nucleotides; at least one of the following connections between nucleotides in the double-stranded RNA is a phosphorothioate connection: The connection between the first nucleotide and the second nucleotide at the 5' end of the sense strand; The connection between the second nucleotide and the third nucleotide at the 5' end of the sense strand; The connection between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; The connection between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; The connection between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
7. The double-stranded RNA according to claim 6, Features: The nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides; or, From 5' to 3', the 12th nucleotide of the antisense strand is a 2'-fluoro-modified nucleotide, and the nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides; or, From the 5' to 3' direction, the nucleotide at position 7 of the antisense strand includes the structural formula The modification shown, wherein R1 is H, OH or CH 3 , Base is a natural nucleobase, a modified nucleobase, a universal base or an H atom; the nucleotide at position 12 of the antisense strand is a 2'-fluoro-modified nucleotide, and the nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides; or, From the 5' to 3' direction, the nucleotide at position 7 of the antisense strand includes the structural formula The modification shown, wherein R1 is H, OH or CH 3 , Base is a natural nucleobase, a modified nucleobase, a universal base or an H atom; and the nucleotides at other positions of the antisense strand are 2'-methoxy-modified nucleotides.
8. The double-stranded RNA according to any one of claims 1 to 3, Features: From 5' to 3', the nucleotides at positions 7, 8 and 9 of the sense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions of the sense strand are 2'-methoxy-modified nucleotides; From 5' to 3', the nucleotides at positions 2, 14 and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions are 2'-methoxy-modified nucleotides; or, the nucleotides at positions 2, 12, 14 and 16 of the antisense strand are 2'-fluoro-modified nucleotides, and the nucleotides at other positions are 2'-methoxy-modified nucleotides; At least one of the following connections between nucleotides in the double-stranded RNA is a phosphorothioate connection: The connection between the first nucleotide and the second nucleotide at the 5' end of the sense strand; The connection between the second nucleotide and the third nucleotide at the 5' end of the sense strand; The connection between the first nucleotide and the second nucleotide at the 5' end of the antisense strand; The connection between the second nucleotide and the third nucleotide at the 5' end of the antisense strand; The connection between the first nucleotide and the second nucleotide at the 3' end of the antisense strand; The connection between the second nucleotide and the third nucleotide at the 3' end of the antisense strand.
9. The double-stranded RNA according to any one of claims 1 to 3, Features: The double-stranded RNA is selected from Table 1, Table 2 or Table 7.
10. The double-stranded RNA according to any one of claims 1 to 3, Features: The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUmUmCmAmUmCfCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUgoUmCmAmUmCfCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmTgoUmCmAmUmCfCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUgoUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGmAfUmGfAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmTgoUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmAmCmAm-3', and the antisense strand is 5'-VP-UmsGfsUmUmUmCfUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmAmCmAm-3', and the antisense strand is 5'-VP-UmsGfsUmUmUmCfUgoUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCfUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCmUmUmCmAmUmCfCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-AmsAmsAmAmCmUmCfCfCfUmCmAmAmCmUmGmGmAmUm-3', and the antisense strand is 5'-AmsUfsCmCmAmGfUmUmGmAmGmGmAfGmUfUmUmUmsGmsCm-3'; or, The sense strand of the double-stranded RNA is 5'-CmsAmsAmGmGmUmGfGfAfGmGmGmUmCmUmCmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmGmAmGfAmCmCmCmUmCmCmAfCmCfUmUmGmsUmsCm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsCmsAmAmCmUmGfGfAfUmGmAmAmGmAmAmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmUmCfUmUmCmAmUmCmCmAfGmUfUmGmAmsGmsGm-3'; or, The sense strand of the double-stranded RNA is 5'-CmsAmsGmCmAmAmAfAfCfUmCmCmCmUmCmAmCmUm-3', and the antisense strand is 5'-AmsGfsUmUmGmAfGmGmGmAmGmUmUmUfUmGfCmUmGmsGmsAm-3'; or, The sense strand of the double-stranded RNA is 5'-CmsCmsAmCmAmAmUfGfAfGmAmGmUmAmCmCmUmGmUm-3', and the antisense strand is 5'-AmsCfsAmGmGmUfAmCmUmCmUmCmAmUfUmGfUmGmGmsAmsUm-3'; or, The sense strand of the double-stranded RNA is 5'-UmsUmsCmUmUmGmGfGfCfUmUmCmCmGmUmAmUmAmUm-3', and the antisense strand is 5'-AmsUfsAmUmAmCfGmGmAmAmGmCmCmCfAmAfGmAmAmsGmsUm-3'; or, The sense strand of the double-stranded RNA is 5'-AmsUmsUmCmCmUmGfUfUfUmGmCmUmGmUmGmUmAmUm-3', and the antisense strand is 5'-AmsUfsAmCmAmCfAmGmCmAmAmAmCmAfGmGfAmAmUmsGmsGm-3'; Among them, the structural formula of Ugo is The structural formula of Tgo is 11. A siRNA conjugate, Features: It comprises the double-stranded RNA according to any one of claims 1 to 10, and a conjugated group conjugated to any position of the double-stranded RNA.
12. The siRNA conjugate according to claim 11, Features: One, two, three or four consecutively connected conjugated groups are connected to any position of the double-stranded RNA.
13. The siRNA conjugate according to claim 11 or 12, Features: The conjugated group is linked to the 3' end and / or the 5' end of the sense strand.
14. The siRNA conjugate according to claim 11, Features: The siRNA conjugate has any one of the following structures: in, represents double-stranded RNA; R represents any one of the conjugated groups having the following structures: Wherein, Y is O or S.
15. A pharmaceutical composition, Features: The invention comprises the double-stranded RNA according to any one of claims 1 to 10 or the siRNA conjugate according to any one of claims 11 to 14, and a pharmaceutically acceptable carrier or excipient.
16. The pharmaceutical composition according to claim 15, Features: The pharmaceutical composition is used for regulating the expression of angiotensinogen AGT.
17. Use of the double-stranded RNA according to any one of claims 1 to 10, or the siRNA conjugate according to any one of claims 11 to 14, or the pharmaceutical composition according to claim 15 or 16 for preparing a medicament for regulating the expression of angiotensinogen AGT.
18. The use according to claim 17, Features: Diseases associated with the expression of angiotensinogen AGT include critical hypertension, essential hypertension, secondary hypertension, isolated systolic or diastolic hypertension, pregnancy-related hypertension, diabetic hypertension, resistant hypertension, refractory hypertension, paroxysmal hypertension, renovascular hypertension, Goldblatt's hypertension, hypertension associated with low plasma renin activity or plasma renin concentration, ocular hypertension, glaucoma, pulmonary hypertension, portal hypertension, systemic venous hypertension, systolic hypertension, unstable hypertension, hypertensive heart disease, Hypertensive nephropathy, atherosclerosis, arteriosclerosis, vascular disease, diabetic nephropathy, diabetic retinopathy, chronic heart failure, cardiomyopathy, diabetic cardiomyopathy, nocturnal hypertension, glomerulosclerosis, aortic coarctation, aortic aneurysm, ventricular fibrosis, heart failure, myocardial infarction, angina pectoris, stroke, kidney disease, renal failure, systemic sclerosis, intrauterine growth retardation, fetal growth restriction, obesity, hepatic steatosis / fatty liver, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, glucose intolerance, type 2 diabetes mellitus and metabolic syndrome.
Citation Information
Patent Citations
Angiotensinogen (agt) irna compositions and methods of use thereof
CN106574268A
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
CN112423795A
Compounds and methods for modulating angiotensinogen expression
CN113817735A
Double-stranded RNA (Ribonucleic Acid) for regulating angiotensinogen gene expression, conjugate of double-stranded RNA, pharmaceutical composition and application of double-stranded RNA
CN117568350A
Angiotensinogen (AGT) irna compositions and methods of use thereof
WO2019222166A1
